Revenue Growth YoY (Last 12 Months): Immutep Limited (IMMP)

Public company logo of Immutep Corp (IMMP)

Immutep Limited (IMMP) is developing cutting-edge treatments for breast and lung cancer, leveraging partnerships with industry behemoths. Laboratory capacities and production lines operate strictly according to the testing schedule. The year-over-year sales trajectory (TTM) clearly demonstrates a trend where the 0.00 parameter determines the metric's magnitude. High funding levels enable the company to attract leading immunologists to implement global scientific programs.

IMMP Immutep Revenue Growth YoY (Last 12 Months) (02/11/2024 - 11/17/2026)

Immutep Corp (IMMP) - metric breakdowns and financial figures

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Immutep Limited, IMMP
Product sample of Immutep Limited ADR

For Immutep Limited, which develops oncology drugs through organic R&D and partnerships, the annual sales volume trend (LTM) serves as an indicator of commercialization efficiency excluding acquisitions. This metric is calculated as the percentage ratio of current revenue over the last 12 months to the same period last year, allowing investors to assess the actual speed of operational scaling and the sustainability of financial growth.